Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 16.23
(-0.55%)
CNY 16.23
(-0.55%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 106.49 Million CNY | 24.29% |
| 2022 | 85.68 Million CNY | 18.78% |
| 2021 | 72.13 Million CNY | -40.63% |
| 2020 | 121.5 Million CNY | 0.97% |
| 2019 | 120.32 Million CNY | 19.68% |
| 2018 | 100.53 Million CNY | 354.35% |
| 2017 | 22.12 Million CNY | -34.46% |
| 2016 | 33.76 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 29.03 Million CNY | 0.13% |
| 2024 Q2 | 49.71 Million CNY | 71.25% |
| 2024 Q3 | 5.13 Million CNY | -89.67% |
| 2023 FY | 106.49 Million CNY | 24.29% |
| 2023 Q1 | 40.56 Million CNY | 193.99% |
| 2023 Q2 | 20.8 Million CNY | -48.71% |
| 2023 Q3 | 16.13 Million CNY | -22.43% |
| 2023 Q4 | 28.99 Million CNY | 79.68% |
| 2022 Q4 | 13.79 Million CNY | -3.25% |
| 2022 Q1 | 29.91 Million CNY | 672.77% |
| 2022 Q3 | 14.26 Million CNY | -48.54% |
| 2022 Q2 | 27.71 Million CNY | -7.37% |
| 2022 FY | 85.68 Million CNY | 18.78% |
| 2021 Q3 | 25.44 Million CNY | -9.82% |
| 2021 Q1 | 23.69 Million CNY | -48.95% |
| 2021 FY | 72.13 Million CNY | -40.63% |
| 2021 Q4 | -5.22 Million CNY | -120.53% |
| 2021 Q2 | 28.21 Million CNY | 19.05% |
| 2020 Q3 | 32.56 Million CNY | 27.6% |
| 2020 Q4 | 46.42 Million CNY | 42.59% |
| 2020 FY | 121.5 Million CNY | 0.97% |
| 2020 Q1 | 16.99 Million CNY | -76.71% |
| 2020 Q2 | 25.51 Million CNY | 50.15% |
| 2019 Q1 | 16.88 Million CNY | 0.0% |
| 2019 FY | 120.32 Million CNY | 19.68% |
| 2019 Q2 | 23.76 Million CNY | 40.75% |
| 2019 Q4 | 72.97 Million CNY | 988.23% |
| 2019 Q3 | 6.7 Million CNY | -71.78% |
| 2018 FY | 100.53 Million CNY | 354.35% |
| 2017 FY | 22.12 Million CNY | -34.46% |
| 2016 FY | 33.76 Million CNY | 0.0% |